a-Monogrid Platform Technology
Moma's a-Monogrid© platform technology utilizes a proprietary biodegradable matrix embedded with monocytes for the biodynamic localized delivery of monocyte's angiogenic vascular growth factors to induce the creation of new blood vessels in target tissues.
Monocyte derived vascular growth factors have shown a therapeutic benefit in cardiovascular and peripheral vascular conditions.
By delivering matrix-contained monocyte clusters into ischemic tissues, Moma's a-Monogrid promotes the formation of collateral vascular systems improving tissue perfusion and regenerating the potency of the damaged tissue, which can result in saving a limb from amputation, improving the function of a damaged heart muscle and healing a chronic wound.
The underlying premise in stem and progenitor cell therapy is the potential of these unique cells to differentiate into functional specialized cells. However, studies indicate that in many cases stem cells benefit is provided through the release of growth factors rather then by cell differentiation.
The a-Monogrid system provide unique conditions in which monocytes act as "angiogenic engines" delivering vascular growth factors together with other proteins necessary for promoting the growth of new blood vessels.
Currently, all cell based therapies targeting ischemic tissues use naked cells hoping that the cells will differentiate and incorporate into the existing tissue. Unfortunately, naked cell delivery results in a very low cell retention. With Moma's a-Monogrid, the cells are confined to the delivery site therefore providing control over the number of cells delivered and increasing the overall control over the therapy outcome.
Advantages of Moma's a-Monogrid technology include: monocytes angiogenic potency, localized delivery, significantly higher cell retention and survival, lack of host immune response, lower regulatory barriers and no political controversies.